Among CD4+ cells, PD1 (+), LAG3 (+), or PD1 (+) LAG3 (+) were all expressed at lower levels after treatment than in untreated DLBCL patients (Figure 3(a)). Here, LAG3 is linked to diffuse large B-cell lymphoma.